Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Noy Shlomo reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund (GIBF), an entity associated with director Noy Shlomo, was granted equity awards in connection with director services provided by GIBF’s CEO and Managing Partner, Avner Lushi. GIBF received fully vested restricted share units that were immediately settled into 9,091 ordinary shares, at a price of
Silexion Therapeutics Corp director Alon Ruth received new equity awards in the form of both shares and options. On February 20, 2026, Ruth was granted 9,091 Ordinary Shares at a price of $0.0000 per share, issued through fully vested restricted share units that were immediately settled into ordinary shares for his board service.
On the same date, he also received a grant of stock options covering 10,685 Ordinary Shares at an exercise price of $0.0000 per share, reflecting compensation for his role as a director. According to the filing, these options vest in full on the one-year anniversary of the grant approval date and expire on the ten-year anniversary of that approval date, providing a long-dated incentive tied to his continued board service. An additional row in the filing simply updates existing option holdings and does not reflect a new transaction.
Shirvan Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp chief scientific and development officer Shirvan Mitchell received a grant of 49,726 fully vested restricted share units that were immediately settled into ordinary shares at no cost, for his services as an officer and approved by the board. Following this award, his direct holdings total 50,707 ordinary shares, and he also directly holds stock options covering 478 ordinary shares, which are reported here for informational purposes only. The share and option amounts reflect prior 1-for-9 and 1-for-15 reverse share splits effective in late 2024 and mid‑2025.
Silexion Therapeutics Corp reported that CFO and Secretary Hadar Mirit Horenshtein acquired 49,726 Ordinary Shares on account of a fully vested restricted share unit grant. The RSUs were immediately settled into ordinary shares as compensation for service as an officer, approved by the board of directors.
Following this grant, Horenshtein directly owns 50,146 Ordinary Shares of Silexion Therapeutics Corp.
Hadar Ilan reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp Chairman and CEO Hadar Ilan received a grant of 64,350 fully vested restricted share units that were immediately settled into ordinary shares at a price of $0.0000 per share, as compensation for officer services and approved by the board. Following this award, Ilan directly holds 65,471 ordinary shares. The filing also lists 956 stock options to buy ordinary shares for informational purposes only, with no new option transaction reported.
Abramov Dror Yosef reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Abramov Dror Yosef reported equity awards on February 20, 2026. He received 9,091 ordinary shares through a grant of fully vested restricted share units that were immediately settled into shares for his director services, as approved by the board.
He was also granted 10,685 stock options to buy ordinary shares, with these options vesting in full on the one-year anniversary of the board’s approval date and expiring ten years after that approval. Following these awards, he held 10,180 ordinary shares directly, and a separate line shows 935 stock options as an existing holding included for informational purposes.
Peled Amnon reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Amnon Peled received equity awards from the company. On February 20, 2026, he was granted 7,576 ordinary shares at no cost through fully vested restricted share units issued for his director services.
On the same date, he was also granted stock options for 8,904 ordinary shares, with the options vesting in full one year after the board’s approval date and expiring ten years after that approval. An additional option holding of 780 shares was reported for informational purposes only, with no transactions effected in that line.
Lushi Avner reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund, an entity associated with director Lushi Avner, received equity awards for director services. The fund was granted 9,091 ordinary shares via fully vested RSUs and 10,685 stock options. These options vest in full on the one-year anniversary of board approval and expire ten years after that approval date. An additional 1,872 stock options are reported as existing holdings with no new transaction.
Silexion Therapeutics Corp is asking shareholders at a March 16, 2026 extraordinary general meeting to approve two key changes. The first would increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, mainly to support financing, business development and compliance with Nasdaq’s $2.5 million shareholders’ equity requirement. The second would amend the 2024 Equity Incentive Plan so the annual “evergreen” refresh can raise the total equity incentive pool up to 10% of issued and outstanding ordinary shares on a fully diluted basis. As of February 23, 2026, Silexion had 3,330,785 ordinary shares outstanding. The board unanimously recommends voting in favor of both proposals.
Silexion Therapeutics Corp received an amended Schedule 13G reporting that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together beneficially own 325,000 ordinary shares, or about 9.4% of the company, as of
The reported position consists entirely of warrants held by Intracoastal Capital LLC, which are exercisable into 325,000 ordinary shares through two separate warrants of 162,500 shares each. All voting and dispositive power over these shares is shared among the reporting persons, with no sole voting or dispositive authority.
An additional 32,100 shares underlying a third warrant are excluded because that warrant has a 4.99% beneficial ownership blocker, which limits exercises that would push the group’s ownership above that threshold.